Our TGEE platform
TargetGene is a pioneer in the field of genome editing and owns the first RNA-guided nuclease system ever invented. This unique proprietary molecular tool, the TargetGene Genome-Editing Engine (TGEE), features unprecedented specificity for its genetic target.
The development of this system combines deep knowledge of protein engineering, molecular gene-editing mechanisms, and cell biology.
The TGEE system has been successfully implemented in human cell lines, and is now being applied to human gene therapy.
The TGEE system will transform gene editing by directly overcoming the main barrier to clinical applications: specificity. TGEE accomplishes this by using a novel genetic guidance system of two guide RNAs. The TGEE system provides a highly efficacious single treatment for a specific medical problem as opposed to chronic treatment. This opens many opportunities for applying the technology towards a variety of therapeutic applications such as heritable diseases, cancer, and immune-disorders, with superior benefit for patients.